• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Enright Patrick G

    5/16/25 4:13:01 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VERA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    ENRIGHT PATRICK G

    (Last) (First) (Middle)
    C/O LONGITUDE CAPITAL MANAGEMENT
    2740 SAND HILL ROAD, 2ND FLOOR

    (Street)
    MENLO PARK CA 94025

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Vera Therapeutics, Inc. [ VERA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/14/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $21.19 05/14/2025 A 14,000 (1) 05/13/2035 Class A Common Stock 14,000 $0 14,000 D
    Explanation of Responses:
    1. The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.
    /s/ Joseph R. Young, Attorney-in-Fact 05/16/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VERA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VERA

    DatePrice TargetRatingAnalyst
    5/5/2025$75.00Buy
    H.C. Wainwright
    2/4/2025$49.00Outperform
    Wolfe Research
    1/28/2025$58.00Buy
    Goldman
    11/21/2024$70.00Overweight
    Wells Fargo
    10/16/2024Sector Outperform
    Scotiabank
    1/25/2024$26.00Outperform
    Oppenheimer
    1/8/2024Overweight
    Cantor Fitzgerald
    12/18/2023$29.00Outperform
    Raymond James
    More analyst ratings

    $VERA
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Vera Therapeutics Inc.

      SCHEDULE 13G - Vera Therapeutics, Inc. (0001831828) (Subject)

      6/11/25 5:38:07 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

      8-K - Vera Therapeutics, Inc. (0001831828) (Filer)

      6/3/25 6:36:50 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Vera Therapeutics, Inc. (0001831828) (Filer)

      6/2/25 6:36:56 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERA
    Leadership Updates

    Live Leadership Updates

    See more
    • Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer

      BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jason S. Carter as Chief Legal Officer, effective immediately. "We are excited to have Jason join our growing team. With our pivotal ORIGIN 3 trial of atacicept in IgAN on track to announce topline results in the second quarter of 2025 and planned BLA submission to the FDA anticipated later in the year, pending data, we are actively building out our team with experienced professionals who will help us succ

      11/18/24 8:00:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer

      BRISBANE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of David L. Johnson as Chief Operating Officer, effective immediately. "We are excited to have David join our executive team at this important time for our clinical program of atacicept for the treatment of IgAN. We expect long-term 96-week data from the Phase 2b ORIGIN trial later this year and primary endpoint results from our pivotal Phase 3 clinical trial in the first half of 2025, and we look forward to

      7/1/24 8:00:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

      BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christy J. Oliger to its board of directors, effective June 7, 2024. Ms. Oliger brings over 30 years of experience in the biopharmaceutical industry, including being recognized for building highly effective teams and leading significant commercial product launches. "We are delighted to welcome Christy to our Board during this important period in Vera's history. Her extensive experience and counsel will be

      6/11/24 4:01:00 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Vera Therapeutics Inc.

      SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

      11/14/24 4:10:28 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vera Therapeutics Inc.

      SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

      11/14/24 4:05:17 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Vera Therapeutics Inc.

      SC 13G - Vera Therapeutics, Inc. (0001831828) (Subject)

      11/14/24 1:22:39 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care